{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P01138",
      "entity_text" : "NGF",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ07831",
      "entity_text" : "IgG2 monoclonal antibody",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Blockade of NGF with tanzeumab, a humanised IgG2 monoclonal antibody against NGF, had robust analgesic effects in OA sufferers XREF_BIBR and more recently lower back pain XREF_BIBR.",
  "reading_complete" : "2020-08-08T17:39:28Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T17:37:19Z",
  "trigger" : "Blockade",
  "evidence" : [ "Blockade of NGF with tanzeumab, a humanised IgG2 monoclonal antibody" ],
  "pmc_id" : "4459966",
  "score" : 0
}